July 23, 2020

Some Encouraging News

The Wall Street Journal reported on June 8th, 2020 that after adjusting for age and co-morbidities, the overall hospital death rate for COVID-19 patients declined by about 40% from March to April 2020.

Some specific improvements were death rate decreases in:

  • People over age 80 from 36.3% to 16.1%

  • Subjects with hypertension from 23% to 12.1%

  • Diabetics from 30.3% to 8.4%

  • Cardiovascular disease patients from 31.5% to 12.1%

  • COPD patients from 29.7% to 11.4%

  • Kidney disease patients from 32.3% to 11.5%

 

This data is from a pre-publication study from Italian universities and local public-health authorities comparing the case-fatality rates in two Italian provinces.

The actual worldwide numbers are likely to significantly differ, but the current consensus is that more hospitalized patients are being saved as front-line physicians rapidly gain a better understanding of COVID-19.

Conversely, these declines in death rates may relate to the egregious state of ignorance everyone had about SARS-CoV-2 treatment when this virus emerged out of virtually nowhere to become pandemic.

As We Learn More, We Realize How Much We Don’t Know

Innovative ICU physicians identified in February-March 2020 the potential value of using IL-6 inhibiting drugs like Actemra® or Kevzara® to suppress the pro-inflammatory “cytokine storm”.


Initial observational and anecdotal reports showed significant reductions in inflammatory biomarkers like C-reactive protein, along with some evidence of improved patient outcomes. 


These favorable findings resulted in Actemra® virtually disappearing from hospital pharmacy shelves as tens of thousands of COVID-10 patients were treated with them. 
A press release by Sanofi-Regeneron in April 2020 provided an interim update on some aspects of the US-based adaptive trial design using Kevzara® in hospitalized patients. 

 

In this press release, the interim report suggested a trend towards a mortality benefit with the high dose 400 mg group in the most critically ill COVID-19 patients   But when Kevzara® was utilized at a lower dose (200 mg) as well as with less critically ill patients, there was a trend towards either neutral or negative outcomes. 
 

Practicing medicine by press release is a poor strategy. But until the final, full clinical trial results are available for critical analysis/peer-review, insights and key pieces of information can only be obtained through press release. Information obtained through press releases needs to be interpreted cautiously.


A major unknown is the precise timing to initiate IL-6 targeted therapy


Also unclear is rapid and early identification of specific COVID-19 patient characteristics that may benefit by targeting excess IL-6


Another drug class with well-known, broad anti-inflammatory effects are corticosteroids. These drugs have been used for years with inconsistent, variable success in patients with acute viral respiratory distress syndromes. 


Preliminary data suggests that dexamethasone may play a beneficial role in treatment of severe COVID-19and may offer a mortality benefit. Until the full results of well-designed studies are released for critical review and analysis, this, too, remains uncertain. 

Anti-Coagulation Drugs

Many of you know of my longstanding advocacy for the use of certain drugs that have significant off-label benefits.

Doctors are now using cocktails of targeted antivirals, anti-coagulants and anti-inflammatory drugs to reduce hospital death rates.


The current standard in many ICUs is to counteract the hyper-coagulable state that causes so much organ damage and mortality in COVID-19 patients. 


Unless contraindicated, many physicians are administering low molecular-weight heparin to help reduce blood clotting that commonly occurs inside blood vessels of COVID-19 patients. 


More physicians are testing D-dimer blood levels to assess if even more aggressive anticoagulant drug therapies should be considered. Here is are two anti-coagulant protocols published by hospitals as it relates to D-dimer levels and use of anticoagulant drugs:


https://www.massgeneral.org/assets/MGH/pdf/news/coronavirus/guidance-from-mass-general-hematology.pdf


https://northmemorial.com/wp-content/uploads/2020/05/inpatient-COVID-thromboprophylaxis-education-5.26.2020.pdf
 

Stay Out of the Hospital

While Better Treatments Emerge

We eagerly await findings from clinical trials on the anti-viral drug remdesivir that will soon be studied in early stage COVID-19.

One plan is to use a nebulizer to create a remdesivir mist that is inhaled directly into the lungs to directly kill the SARS-CoV-2 virus. This will likely be available on an outpatient basis, thereby eliminating the need for hospitalization for certain COVID-19 patients.

This is reminiscent of the early days of treating HIV where an anti-bacterial drug called pentadamine was used in Europe in aerosolized form to kill the Pneumocystis carinii bacteria. This was the leading cause of pneumonia death in AIDS patients back then.

Pentadamine was approved in the U.S. in tablet form but had to be imported by AIDS Buyers Clubs from other countries to extend the lives of immune-suppressed AIDS victims.

The problem today is a shortage of remdesivir, so there is no country from which it can be imported now to potentially eradicate COVID-19 from the lungs of patients.

Within the next 3-5 months, there may be enough remdesivir available with which to reliably treat American COVID-19 patients.

Our Covid-19 Website

More people are dying from COVID-19, but the percent of hospitalized patients who die (i.e. the “death rate”) is decreasing as more innovative, multi-modal, medication cocktails are administered.

The population of hospitalized patients may also be shifting to younger, heathier groups as high-risk groups like the elderly, obese, hypertensive and/or diabetic shelter in place.

 

While the death rate is declining, many of those who recover from COVID-19 are suffering long- term disorders ranging from cognitive impairment, fatigue, and organ dysfunctions.

Our COVID-19 website (www.age-reversal-covid.net) does not cover every potential treatment, but seeks to highlight data that may be overlooked by heroic frontline physicians.

We have been posting updates every few days, but it is impossible to create a concise COVID-19 treatment protocol that many of you have requested.  This must be done by ICU physicians based on their experience, knowledge, and condition of the individual patient.

I realize there is a LOT of data posted on our COVID website that is challenging to navigate through.

I did not expect so much new data would be uncovered when I started drafting the website in March 2020.

Challenges with Vaccines

Vaccines work by inducing the body to produce antibodies against a specific antigen.

An effective vaccine against SARS-CoV-2 will require continuous production of specific neutralizing antibodies.

The problem is that as people age, their ability to mount an effective antibody response becomes significantly impaired.

That’s why we focus so much of our age reversal research on improving immune function. As the data clearly shows, younger persons with healthier immune responses are far less likely to succumb to COVID-19.

An advance in improving antibody responses in older people will make vaccines far more effective.

Treatment Improvements

Treatment improvements may continue to reduce the death rate from COVID-19.

 

The latest results of the breakthrough nebulized interferon-beta trial are only a glimpse at the treatment improvements that will come soon. 


That’s why it is so important that we take extraordinary steps to maintain healthy immune functions today, and I am grateful to be writing to an audience who has understood this concept for many decades.

The prospect of more effective COVID-19 treatments being available later this year should also motivate you to take precautions against infection, which means limiting social contacts and wearing the most effective face mask you can find when in public. (I wish I had a reliable face mask source to refer you to.)

The bottom line is, you don’t want to be among the last to perish from COVID-19 when effective therapies—perhaps nebulizer-delivered remdesivir—might be available soon if clinical trials yield favorable results.

Our Battle Against Biological Aging

Scientists today describe the potential of mitigating the COVID-19 pandemic by restoring more youthful immune function to elderly persons who are most vulnerable to significant disease manifestations.

That’s exactly what members of our Age Reversal Network have been seeking since 2013.

If we can induce even a modest restoration of youthful immune function, especially a more robust antibody response and enhanced natural-killer cell activity, the lives of older COVID-19 victims might be spared.

I value your feedback, and I am sorry I cannot reply to your many questions.

My primary focus remains on advancing age-reversal therapies, which ultimately will protect us against virtually every infectious and degenerative illness.

For longer life,

 
William Faloon, Volunteer

 

P.S. The Age Reversal Network is an informal association, with no funding for staff. If you inquire to us with questions, please be patient with communication delays, as we have minimal staff to answer questions of a few thousand people currently registered to receive updates.

You can read many of our previous email updates here.  

About the Age Reversal Network (Age-Reversal.net)

The purpose of the Age Reversal Network is to exchange scientific information, foster strategic alliances, and support biomedical endeavors aimed at reversing degenerative aging.
 
We seek to unite people in ways that will accelerate the availability of rejuvenation technologies to benefit all of humanity, including members of the group. As data emerges, the Age Reversal Network will seek to rapidly convey this to members of our private association.
 
The Age Reversal Network consists of a few thousand individuals who have expressed their desire to donate, invest, and/or actively participate in advancing human age reversal studies.

Our public benefit group functions as a private association and consists of physicians, scientists, activists, investors, donors, and participants in previous age reversal initiatives. These individuals share a common desire to rejuvenate aged people. 

Partnerships may form within or outside the group in any manner the individual members choose. Information will be shared at the discretion of the individual members.
 
The Age Reversal Network serves as an open-source communications channel to a wide variety of experimental technologies. There are some individuals in this group who are bound by confidentiality/nondisclosure contracts. We nonetheless welcome their input and any meaningful scientific data they are permitted to disseminate. A key to our success will be open-source information sharing whenever feasible.
 
Those who choose to participate in clinical trials or self-experiment with therapies described by the Age Reversal Network should do so with the knowledge that any intervention can have unknown risks.
 
Members of this private association acknowledge they are embarking on a voyage with historic implications relating to human longevity. As with any exploratory venture, the outcome cannot be predicted and any medical intervention carries inherent risks, especially for elderly individuals. Professional medical advice should be sought before undergoing any potential treatment you learn about from the Age Reversal Network
  
To register as a member of the Age Reversal Network and receive updates about regenerative medicine research initiatives, please log on to
Age-Reversal.net/join and register with your information there.

Latest News